Summit Therapeutics' Ivonescimab: A Promising Competitor to Keytruda with Enhanced Approval Probability and Price Target of $50.00

Summit Therapeutics' ivonescimab has shown promising efficacy in EGFR-mutant non-small cell lung cancer, positioning it as a competitor to Keytruda. Analyst Mitchell Kapoor maintains a Buy rating and increases the probability of approval in NSCLC to 85%, raising the 12-month price target to $50.00. The drug's strong potential to surpass Keytruda's commercial success is highlighted by its overall survival benefits.

Summit Therapeutics' (SMMT) experimental drug, ivonescimab, has demonstrated significant potential in treating EGFR-mutant non-small cell lung cancer (NSCLC). The drug has shown promising overall survival (OS) benefits, positioning it as a strong competitor to Merck & Co. Inc.'s (MRK) Keytruda. Analysts have responded positively to these findings, with Mitchell Kapoor of H.C. Wainwright maintaining a Buy rating and increasing the probability of approval in NSCLC to 85%, raising the 12-month price target to $50.00.

Kapoor's confidence is bolstered by recent clinical trial results, particularly the overall survival (OS) win in China for EGFR-mutant NSCLC. The drug's progression-free survival (PFS) benefits have translated into OS improvements, making it a formidable competitor to Keytruda, which failed to show similar OS benefits in its trials. The comparability of the HARMONi trial results between Chinese and ex-China patients suggests that the OS data will achieve statistical significance as it matures.

The market's previous overreactions to interim OS analyses, which lacked maturity, are now being corrected with this new data. Kapoor has raised the probability of approval in NSCLC to 85% and raised the 12-month price target for Summit Therapeutics to $50, reflecting the strong potential for ivonescimab to surpass Keytruda’s commercial success.

Summit Therapeutics will present HARMONi data at the World Conference on Lung Cancer in Barcelona, Spain in early September, followed by HARMONi-6 squamous NSCLC data in October at ESMO in Berlin, Germany. The firm identified the next HARMONi-2 OS analysis by year-end 2025 as the most important near-term catalyst, which it believes will demonstrate that ivonescimab’s PFS advantage versus Keytruda is translating into OS benefit, potentially positioning the drug to compete with Keytruda’s $30 billion annual franchise.

Analyst activity around Summit Therapeutics has been notable. TD Cowen reiterated its Buy rating, emphasizing the positive outcomes from the HARMONi-A trial. UBS also maintained its Buy rating, highlighting upcoming data updates expected at the World Conference on Lung Cancer. Meanwhile, Piper Sandler initiated coverage with a Neutral rating, expressing concerns about rising investor expectations. JMP Securities reiterated a Market Outperform rating, setting a price target of $40.00. These developments present a mixed but overall optimistic picture for Summit Therapeutics according to various analysts.

References:
1. [https://www.tipranks.com/news/ratings/summit-therapeutics-ivonescimab-a-promising-competitor-to-keytruda-with-increased-approval-probability-and-price-target-ratings](https://www.tipranks.com/news/ratings/summit-therapeutics-ivonescimab-a-promising-competitor-to-keytruda-with-increased-approval-probability-and-price-target-ratings)
2. [https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/08/47367794/summit-akeso-report-lung-cancer-survival-boost-with-ivonescimab-a-rival-to-mercks-keytruda-multi-billion-dollar-franchise-says-analyst](https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/08/47367794/summit-akeso-report-lung-cancer-survival-boost-with-ivonescimab-a-rival-to-mercks-keytruda-multi-billion-dollar-franchise-says-analyst)
3. [https://ca.investing.com/news/analyst-ratings/summit-therapeutics-stock-price-target-raised-to-50-from-44-at-hc-wainwright-93CH-4178198](https://ca.investing.com/news/analyst-ratings/summit-therapeutics-stock-price-target-raised-to-50-from-44-at-hc-wainwright-93CH-4178198)